TissueTech raises capital in private placement to Ballast Point Ventures entities and River Cities Capital

Client(s) TissueTech, Inc.

Jones Day represented TissueTech, Inc., a provider of regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal, and wound care markets, in connection with its issuance of $10 million of Series A Preferred Stock in a private placement to Ballast Point Ventures II, L.P.; Ballast Point Ventures EF II, L.P.; and River Cities Capital Fund V, L.P.